Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma

Llano, Luís Pérez de; Naval, Elsa; Mejía, Natalia; Domínguez‐Ortega, Javier

doi:10.1080/17476348.2021.2005585

Expert Review of Respiratory Medicine

2021

DOI: 10.1080/17476348.2021.2005585

|View full text |Cite

Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma

Luís Pérez de Llano

Elsa Naval

Natalia Mejía

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Relationship between Prices of Fixed-dose and Free-equivalent Combination: A Survey of Medicines in China's National Reimbursement Drug List

FENG,

Li,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives This study investigates the relationship between the prices of fixed-dose combinations (FDCs) and free-equivalent combinations (FECs) within China's National Reimbursement Drug List (NRDL). The focus is on comparing their price ratios.Methods We identified FDCs and FECs listed in the NRDL, along with recent bidding data. Publicly listed prices and characteristics of these medications were collected from Chinese government websites and commercial databases. Price ratios were calculated after adjusting for the active pharmaceutical ingredient's strength and dosage form, following the "Chinese Pharmaceutical Differential Pricing Rules."Results The analysis showed that the price ratios of FDCs to FECs in the NRDL averaged 1.11 ± 0.77 (Mean ± Standard Deviation). The price ratios varied significantly across different therapeutic areas, with the highest ratios observed in cardiovascular system drugs, followed by systemic anti-infective agents, digestive tract and metabolism drugs, and respiratory system drugs. FDCs in the negotiation catalog had lower and more stable price ratios compared to those in the regular catalog. The significant price reduction of FECs or FDCs due to the volume-based procurement (VBP) program also affected their price ratios.Conclusions The relationship between the prices of FDCs and FECs within China's NRDL is not clearly defined. These price ratios vary substantially across different therapeutic areas and drug categories and are influenced by the VBP program. These findings provide valuable insights for decision-makers on pricing strategies for newly reimbursed FDCs.

show abstract

Relationship between Prices of Fixed-dose and Free-equivalent Combination: A Survey of Medicines in China's National Reimbursement Drug List

FENG,

Li,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma

Cited by 1 publication

References 94 publications

Relationship between Prices of Fixed-dose and Free-equivalent Combination: A Survey of Medicines in China's National Reimbursement Drug List

Relationship between Prices of Fixed-dose and Free-equivalent Combination: A Survey of Medicines in China's National Reimbursement Drug List

Contact Info

Product

Resources

About